GLP1R and type 2 diabetes mellitus: However, T2D patients treated with GLP-1 mimetics still experience disease progression eventually requiring insulin therapy, and extensive efforts to improve the use of gut hormone-based therapy are focused on the rational design of combinations that are superior to monotherapy due to synergistic or additive effects on glucose control and weight loss.